ManidipineCalcium channel blocker CAS# 89226-50-6 |
- Zileuton
Catalog No.:BCC2515
CAS No.:111406-87-2
- Zileuton sodium
Catalog No.:BCC4216
CAS No.:118569-21-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 89226-50-6 | SDF | Download SDF |
PubChem ID | 4008 | Appearance | Powder |
Formula | C35H38N4O6 | M.Wt | 610.7 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO > 10 mM | ||
Chemical Name | 5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | ||
SMILES | CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC | ||
Standard InChIKey | ANEBWFXPVPTEET-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C35H38N4O6/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-16,23,32-33,36H,17-22H2,1-3H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Manidipine Dilution Calculator
Manidipine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6375 mL | 8.1873 mL | 16.3747 mL | 32.7493 mL | 40.9366 mL |
5 mM | 0.3275 mL | 1.6375 mL | 3.2749 mL | 6.5499 mL | 8.1873 mL |
10 mM | 0.1637 mL | 0.8187 mL | 1.6375 mL | 3.2749 mL | 4.0937 mL |
50 mM | 0.0327 mL | 0.1637 mL | 0.3275 mL | 0.655 mL | 0.8187 mL |
100 mM | 0.0164 mL | 0.0819 mL | 0.1637 mL | 0.3275 mL | 0.4094 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Manidipine is a calcium channel blocker that is used clinically as an antihypertensive.Manidipine is a dihydropyridine calcium antagonist, which causes systemic vasodilation by inhibiting the voltage-dependent calcium inward currents in smooth muscle cell
- LY2334737
Catalog No.:BCC4060
CAS No.:892128-60-8
- Mulberrofuran H
Catalog No.:BCN3371
CAS No.:89199-99-5
- Fraxiresinol 1-O-glucoside
Catalog No.:BCN4439
CAS No.:89199-94-0
- Efaroxan hydrochloride
Catalog No.:BCC6797
CAS No.:89197-00-2
- 15,16-Dihydrotanshindiol C
Catalog No.:BCN3214
CAS No.:891854-96-9
- 1,2-Didehydrocryptotanshinone
Catalog No.:BCN3122
CAS No.:891854-92-5
- 15,16-Dihydrotanshindiol B
Catalog No.:BCN3213
CAS No.:891854-86-7
- SCH900776 S-isomer
Catalog No.:BCC1936
CAS No.:891494-64-7
- MK-8776 (SCH-900776)
Catalog No.:BCC3817
CAS No.:891494-63-6
- Betulin caffeate
Catalog No.:BCN4438
CAS No.:89130-86-9
- Odoratisol A
Catalog No.:BCN7813
CAS No.:891182-93-7
- 4-O-Demethylisokadsurenin D
Catalog No.:BCN6650
CAS No.:89104-59-6
- Manidipine 2HCl
Catalog No.:BCC4405
CAS No.:89226-75-5
- AZD 3988
Catalog No.:BCC5621
CAS No.:892489-52-0
- 2-(Chloromethyl)-4-(4-nitrophenyl)-1,3-thiazole
Catalog No.:BCC8372
CAS No.:89250-26-0
- MF63
Catalog No.:BCC1744
CAS No.:892549-43-8
- 2,4-Dihydroxy-3-nitropyridine
Catalog No.:BCC8499
CAS No.:89282-12-2
- 3,4-O,O-Methylene-(+)-catechin
Catalog No.:BCN7962
CAS No.:89329-14-6
- ICI 174,864
Catalog No.:BCC5675
CAS No.:89352-67-0
- Chiisanoside
Catalog No.:BCN2712
CAS No.:89354-01-8
- Riligustilide
Catalog No.:BCC9136
CAS No.:89354-45-0
- PF 945863
Catalog No.:BCC6172
CAS No.:893556-85-9
- Imidapril HCl
Catalog No.:BCC3792
CAS No.:89396-94-1
- VU 0240551
Catalog No.:BCC5424
CAS No.:893990-34-6
Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine.[Pubmed:27885840]
Future Cardiol. 2017 Mar;13(2):143-151.
AIMS: In AMANDHA trial, the addition of Manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions. Factors associated with the reduction of UAE were analyzed. METHODS: For this purpose, a multivariable analysis was performed. RESULTS: Although after 6 months of treatment, Manidipine and amlodipine decreased BP to a similar extent, reductions of UAE were higher with Manidipine. The assigned treatment, changes in mean BP, sympathetic tone and glycemic control were associated with changes in UAE. CONCLUSION: The assigned treatment, changes in mean BP, sympathetic tone and glycemic control were independently associated with changes in UAE. Compared with amlodipine, Manidipine reduced UAE to a higher extent, independently of BP reduction.
Improved stability of solid dispersions of manidipine with polyethylene glycol 4000/copovidone blends: application of ternary phase diagram.[Pubmed:27874293]
Drug Dev Ind Pharm. 2017 Mar;43(3):483-491.
CONTEXT: Manidipine (MDP) is generally used clinically as an antihypertensive agent; however, the bioavailability of orally administered MDP is limited due to their very low water solubility. OBJECTIVE: The objectives of this research were, therefore, to increase the solubility of MDP by the formation of ternary solid dispersions (tSD) with polyethylene glycol 4000 (PEG4000) and copovidone and to improve their stability. METHODS: Solid ternary phase diagram was constructed to find homogeneous solid dispersion region after melting and solidifying at low temperature with different quenching substances. The pulverized powder of solid dispersions was then determined, for their physicochemical properties, by differential scanning calorimetry, powder X-ray diffractometry, Fourier transform infrared (FTIR) spectroscopy and hot stage microscopy. The solubility and dissolution of MDP from the tSD were investigated. The physical stability of tSD was also determined under accelerated condition at 40 degrees C/75% relative humidity (RH) for 6 months. RESULTS AND DISCUSSION: The results showed that MDP was molecularly dispersed in PEG4000 and copovidone when the tSD was created from homogeneous region of solid ternary phase diagram. FTIR results confirmed that strong hydrogen bonding was presented between MDP and copovidone, leading to a significant increase in the solubility and dissolution of MDP. After storage at accelerated condition (40 degrees C/75%RH) for 6 months, the tSD still showed a good appearance and high solubility. CONCLUSION: The results of this study suggest that tSD prepared by melting has promising potential for oral administration and may be an efficacious approach for improving the therapeutic potential of MDP.
Treatment of hypertensive patients with diabetes: beyond blood pressure control and focus on manidipine.[Pubmed:27221471]
Future Cardiol. 2016 Jul;12(4):435-47.
Renin-angiotensin system inhibitors should be considered as the first-line therapy in the treatment of patients with hypertension and diabetes. However, most of the diabetic subjects with hypertension require at least two drugs to achieve blood pressure targets. The ACCOMPLISH trial suggested that the best combination in the treatment of high-risk hypertensive patients should include a renin-angiotensin system inhibitor and a dihydropyridine. However, not all dihydropyridines block the same receptors. Those dihydropyridines that block T-type calcium channel blockers may provide additional advantages. A number of studies suggest that compared with amlodipine, Manidipine have the same antihypertensive efficacy, but with a lesser risk of ankle edema. In addition, Manidipine, but not amlodipine, significantly reduces urinary albumin excretion rates.
Stability-indicating micellar electrokinetic chromatography technique for simultaneous measurement of delapril and manidipine from a combination drug formulation.[Pubmed:24672867]
J AOAC Int. 2014 Jan-Feb;97(1):114-20.
A stability-indicating micellar electrokinetic chromatography (MEKC) method was developed and validated for simultaneous analysis of delapril (DEL) and Manidipine (MAN) using salicylic acid as an internal standard. The MEKC method was performed using a fused-silica capillary (effective length of 72 cm) with 50 mM of borate buffer and 5 mM of anionic surfactant sodium dodecylsulfate at pH 9.0 as the background electrolyte. The separation was achieved at 25 kV applied voltage and 35 degrees C. The injection was performed at 50 mbar for 5 s, with detection at 208 nm. The method was linear in the range of 15-150 microg/mL (r2 = 0.9966) for DEL and 5-50 microg/mL (r2 = 0.9985) for MAN with adequate results for the precision (< or = 1.87%) and accuracy (98.94% for DEL and 100.65% for MAN). The specificity of the method and its stability-indicating capability was demonstrated through forced degradation studies, which showed that there was no interference from the excipients. The Plackett-Burman experimental design was used for robustness evaluation, giving results within the acceptable range. The method was successfully applied for analysis of the drugs, and the results were compared to an LC method, resulting in nonsignificant differences (P = 0.78 and 0.84 for DEL and MAN, respectively).